Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercept, Madrigal Get Ready For NASH Commercialization

Mar 02 2023

• By Joseph Haas

liver — Intercept, Madrigal may be heading toward approval in NASH

Related Content

Viking Phase II Update Shows Sustained Response After Treatment’s End

Aug 28 2020

Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients

Aug 13 2020

Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J

Feb 15 2023

ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA

Feb 16 2023

Imminent Madrigal, Viking Trial Readouts Will Shape NASH R&D Expectations

Nov 09 2022

Intercept Gifts Shareholders With NASH Refiling

Dec 23 2022

Madrigal Phase III Success In NASH Spurs Buyout Speculation

Dec 19 2022

Related Companies

Viking Therapeutics, Inc.

Intercept Pharmaceuticals, Inc.

Johnson & Johnson

Arrowhead Pharmaceuticals, Inc.

Novartis AG

Pliant Therapeutics, Inc.

Merck & Co., Inc.

NGM Biopharmaceuticals, Inc.

Bristol Myers Squibb Company

Eli Lilly and Company

Pfizer Inc.

Additional Topics

Business Strategies Clinical Trials Drug Approval Standards Research & Development Liver & Hepatic BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window